Ovata Capital Management Ltd Makes New $146,000 Investment in Agenus Inc. $AGEN

Ovata Capital Management Ltd bought a new position in shares of Agenus Inc. (NASDAQ:AGEN) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 32,000 shares of the biotechnology company’s stock, valued at approximately $146,000.

A number of other large investors have also recently added to or reduced their stakes in AGEN. Apollon Wealth Management LLC boosted its position in Agenus by 25.0% during the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 5,000 shares during the period. Acadian Asset Management LLC bought a new stake in Agenus during the first quarter worth approximately $58,000. Bank of Montreal Can bought a new stake in Agenus during the second quarter worth approximately $75,000. Wealth Enhancement Advisory Services LLC bought a new stake in Agenus during the second quarter worth approximately $85,000. Finally, Invesco Ltd. bought a new stake in Agenus during the first quarter worth approximately $88,000. Institutional investors own 61.46% of the company’s stock.

Agenus Trading Down 1.1%

Shares of NASDAQ AGEN opened at $3.69 on Thursday. The business has a fifty day simple moving average of $4.19 and a 200 day simple moving average of $4.45. The firm has a market capitalization of $117.58 million, a price-to-earnings ratio of -0.52 and a beta of 1.43. Agenus Inc. has a one year low of $1.38 and a one year high of $7.34.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million during the quarter, compared to analyst estimates of $49.71 million. On average, research analysts anticipate that Agenus Inc. will post -12.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on AGEN shares. HC Wainwright reiterated a “buy” rating on shares of Agenus in a report on Monday, October 20th. Zacks Research upgraded Agenus to a “hold” rating in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Agenus in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.50.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.